RBM5 and breast carcinoma: Our data revealed that hypoxia-induced RBM5-AS1 activates Wnt/β-catenin signaling pathway through upregulating as well as binding β-catenin to facilitate breast cancer initiation and progression, with implications of RBM5-AS1 as a promising therapeutic target for breast cancer.